promo_leaderboard Ad
‹ All stocks
RYTM

Rhythm Pharmaceuticals

RYTM · NASDAQ · Healthcare
$106.22
▼ $1.26 (-1.17%)
$83.59 $94.07 $104.54 $115.02 $106.22 Oct 18 Nov 02 Nov 17
Day range
$105.87 – $107.68
Year range
$74.50 – $122.20
Open
$106.81
Previous close
$107.48
Market cap
$7.36B
Volume (24h)
$58.2K
Volume (52w)
$6.18M
Performance
7D
▼ -6.78%
1M
▲ 20.39%
3M
▼ -8.22%
6M
▲ 17.77%
1Y
▲ 5.49%
YTD
▲ 1.15%
3Y
▲ 218.60%
5Y
▲ 828.50%
All-time
▲ 332.32%
Key statistics
P/E ratio
-36.63
EPS (TTM)
$-2.90
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
69.3M
About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

Visit website
Country: United States of America
Related news
More in Healthcare